3-{1-[2,5-Dioxo-1-(2'-sulfamoyl-biphenyl-4-yl)-pyrrolidin-(3Z)-ylidene]-ethyl}-benzimidic acid methyl ester | 534576-02-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-{1-[2,5-Dioxo-1-(2'-sulfamoyl-biphenyl-4-yl)-pyrrolidin-(3Z)-ylidene]-ethyl}-benzimidic acid methyl ester
• CAS: 534576-02-8
• 化学式: C₂₆H₂₃N₃O₅S
• 分子量: 489.552
• InChiKey: HBYWLPYFKXWANL-MTTLQMSQSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.71
• 重原子数：
  35.0
• 可旋转键数：
  5.0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  130.62
• 氢给体数：
  2.0
• 氢受体数：
  6.0

反应信息

• 作为反应物：
  描述：

  3-{1-[2,5-Dioxo-1-(2'-sulfamoyl-biphenyl-4-yl)-pyrrolidin-(3Z)-ylidene]-ethyl}-benzimidic acid methyl ester 在 肼 作用下， 以 甲醇 为溶剂， 生成 N'-amino-3-[(1Z)-1-[2,5-dioxo-1-[4-(2-sulfamoylphenyl)phenyl]pyrrolidin-3-ylidene]ethyl]benzenecarboximidamide
  参考文献：
  名称：

  Design and synthesis of factor Xa inhibitors and their prodrugs

  摘要：

  In addition to our previously reported fluoro acrylamides Xa inhibitors 2 and 3, a series of potent and novel cyclic diimide amidine compounds has been identified. In efforts to improve their oral bioavailability, replacement of the amidine group with methyl amidrazone: gives compounds of moderate potency (14, IC50 = 0.028 muM). In the amidoxime prodrug approach, the amidoxime compounds show good oral bioavailability in rats and dogs. High plasma level of prodrug 26 and significant concentration of active drug 26a were obtained upon oral administration of prodrug 26 in rats. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)00921-6
• 作为产物：
  描述：

  2-(4-氨基苯基)-N-叔丁基苯磺酰胺 在 盐酸 、 (benzotriazo-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate 、 三乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 3-{1-[2,5-Dioxo-1-(2'-sulfamoyl-biphenyl-4-yl)-pyrrolidin-(3Z)-ylidene]-ethyl}-benzimidic acid methyl ester
  参考文献：
  名称：

  Design and synthesis of factor Xa inhibitors and their prodrugs

  摘要：

  In addition to our previously reported fluoro acrylamides Xa inhibitors 2 and 3, a series of potent and novel cyclic diimide amidine compounds has been identified. In efforts to improve their oral bioavailability, replacement of the amidine group with methyl amidrazone: gives compounds of moderate potency (14, IC50 = 0.028 muM). In the amidoxime prodrug approach, the amidoxime compounds show good oral bioavailability in rats and dogs. High plasma level of prodrug 26 and significant concentration of active drug 26a were obtained upon oral administration of prodrug 26 in rats. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)00921-6